Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
The Journal of Urology
|
October 5, 2023
Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
E David Crawford, Jason M Hafron, Frans Debruyne, et al.
Urology
|
November 20, 2003
An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists
Michael Koch, Christopher Steidle, Stanley Brosman, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer
Shekman L Wong, David T-W Lau, Sharon A Baughman, et al.
BJU International
|
July 6, 2013
The utility of prostate-specific antigen in the management of advanced prostate cancer
E David Crawford, Charles L Bennett, Gerald L Andriole, et al.
Journal of Clinical Pharmacology
|
April 23, 2004
Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75
Shekman L Wong, David T-W Lau, Sharon A Baughman, et al.
The Journal of Urology
|
December 21, 2010
Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance
Ignacio F San Francisco, Lillian Werner, Meredith M Regan, et al.
The Journal of Urology
|
March 26, 2002
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
John Trachtenberg, Marc Gittleman, Christopher Steidle, et al.
The Canadian Journal of Urology
|
April 20, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
David E Crawford, David Albala, Marc B Garnick, et al.
Urologic Oncology
|
March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy
E David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Urology Practice
|
December 5, 2023
Reply by Authors
E David Crawford, Marc B Garnick, Robert H Eckel, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
The Journal of Urology
|
October 5, 2023
Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
E David Crawford, Jason M Hafron, Frans Debruyne, et al.
Urology
|
November 20, 2003
An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists
Michael Koch, Christopher Steidle, Stanley Brosman, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer
Shekman L Wong, David T-W Lau, Sharon A Baughman, et al.
BJU International
|
July 6, 2013
The utility of prostate-specific antigen in the management of advanced prostate cancer
E David Crawford, Charles L Bennett, Gerald L Andriole, et al.
Journal of Clinical Pharmacology
|
April 23, 2004
Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75
Shekman L Wong, David T-W Lau, Sharon A Baughman, et al.
The Journal of Urology
|
December 21, 2010
Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance
Ignacio F San Francisco, Lillian Werner, Meredith M Regan, et al.
The Journal of Urology
|
March 26, 2002
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
John Trachtenberg, Marc Gittleman, Christopher Steidle, et al.
The Canadian Journal of Urology
|
April 20, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
David E Crawford, David Albala, Marc B Garnick, et al.
Urologic Oncology
|
March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy
E David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Urology Practice
|
December 5, 2023
Reply by Authors
E David Crawford, Marc B Garnick, Robert H Eckel, et al.
Page
of 5